Optimal Timing of Ketamine Initiation for SCD Pain

Starting soon · Phase 3 · Has a placebo group

Conditions studied: Sickle Cell Disease, Sickle Cell Crisis

In brief

The goal of this clinical trial is to learn if the use of early ketamine decreases the chance of admission to the hospital in patients with sickle cell disease presenting with pain. The main questions this study aims to answer are: * Does ketamine given within 1 hour of acute care presentation decrease the chance of hospital admission? * If admitted, does continuing ketamine in the first few hours of admission decrease opioid use or length of stay compared to those who start it later in the admission? Researchers will compare the study arm to patients with sickle cell disease who receive placebo within 1 hour of presentation for the first aim. Participants will be given ketamine/placebo by mouth without 1 hour of presentation. If admitted, all participants will be able to start open label IV ketamine upon admission to the floor based on their clinical needs. Participants who end up starting ketamine will be reviewed to determine if early start to ketamine is helpful in reducing opioid use and length of stay.

Key facts

Study ID

NCT07450430

Run by

Boston Children's Hospital

People needed

90

Starts

2026-02-01

Expected to finish

2030-02-01

Last updated by the study team

2026-03-09

Who can join

Age: 6 and older, up to 24. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• sickle cell disease diagnosis
• presenting with pain to ED or infusion clinic
• patient at study site
• 6 to 24 years old

You may not qualify if…

• allergy to ketamine
• severe side effects associated with ketamine
• unable to consent

Where it is running

• Boston Children's Hospital — Brookline, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.